Pharma Stability: Insights, Guidelines, and Expertise
Not all pharmaceutical products present the same stability risks. Factors such as chemical structure, formulation, packaging, and manufacturing consistency determine degradation pathways. By evaluating these variables systematically, teams can:
Click to read the full article.
Stability protocols guide long-term product performance verification. However, a poorly designed protocol can result in:
Click to read the full article.
Agencies like USFDA and EMA expect that companies use Quality Risk Management (QRM) principles when designing stability protocols. However, such flexibility demands thorough documentation. Regulatory queries often arise due to:
Click to read the full article.
Auditors reviewing risk-based stability studies will typically focus on:
Click to read the full article.
Historical data serves multiple roles in protocol design:
Click to read the full article.
A risk-scoring template is a standardized worksheet or software form that allows you to:
Click to read the full article.
Bracketing is a strategy where only the extremes of certain variables (such as strength, container size, or fill volume) are tested. The assumption is that intermediate levels will exhibit stability similar to the extremes.
Click to read the full article.
Gone are the days when exhaustive data alone sufficed. Today’s regulatory bodies such as CDSCO and USFDA emphasize lifecycle risk management. They expect manufacturers to:
Click to read the full article.
Every dataset that supports a risk-based justification must comply with ALCOA+ principles:
Click to read the full article.
Initial risk assessments are based on limited clinical and development data. Once the product is scaled up and released to multiple markets, new variables—like packaging materials, storage locations, and temperature excursions—can alter the risk landscape. Reassessing your stability risk profile ensures:
Click to read the full article.